Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) COO Sells 120,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) COO Ryan Fukushima sold 120,000 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total value of $5,101,200.00. Following the completion of the transaction, the chief operating officer now directly owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. This trade represents a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Trading Down 2.4 %

Shares of NASDAQ:TEM traded down $0.99 during midday trading on Friday, reaching $41.00. 5,041,241 shares of the company were exchanged, compared to its average volume of 1,427,998. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The stock's fifty day moving average price is $52.88. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently modified their holdings of the company. First Horizon Advisors Inc. bought a new position in shares of Tempus AI during the 3rd quarter worth approximately $30,000. Sandia Investment Management LP acquired a new position in Tempus AI during the second quarter worth $136,000. Vestor Capital LLC bought a new position in Tempus AI in the third quarter valued at $153,000. Stifel Financial Corp acquired a new stake in Tempus AI in the 3rd quarter valued at $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Tempus AI during the 3rd quarter worth about $258,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Analyst Upgrades and Downgrades

TEM has been the subject of a number of recent analyst reports. Loop Capital upped their price objective on Tempus AI from $48.00 to $57.00 and gave the company a "buy" rating in a report on Tuesday, October 15th. Bank of America upped their price target on Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research note on Friday. Piper Sandler reissued a "neutral" rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Friday. They issued an "outperform" rating and a $60.00 target price for the company. Finally, Stifel Nicolaus lowered shares of Tempus AI from a "buy" rating to a "hold" rating and increased their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.